The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings - CNBC
Sentiment Mix
Geography
Expert Signals
Politics - Google News US Headlines
source • 1 mention
AI-Generated Claims
Generated from linked receipts; click sources for full context.
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
Supported by 1 story
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings CNBCLilly climbs, Novo falls as obesity drug battle intensifies BioPharma DiveHow Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs.
Supported by 1 story
MarketWatchLilly confident in slow and steady Foundayo launch, as ex-US sales shine BioSpaceLilly's obesity pill Foundayo ‘disappointed' in Q2, as injectables continue to boom Fierce Pharma
Supported by 1 story
Related Events
S&P 500 struggles for direction as investors await Mideast deal; software stocks slide - Reuters
Uncategorized • 8/6/2026
Google seeks a sharper focus in AI after Hassabis move - Financial Times
Uncategorized • 8/6/2026
Google’s DeepMind Shakeup Weakens UK Bid to Stay in AI Race - Bloomberg.com
Uncategorized • 8/6/2026
Investment tips for the booming stock market
Industry • 8/6/2026
Why Sandisk and Western Digital crashed 10% and what it means for bitcoin - CoinDesk
Uncategorized • 8/6/2026